- AM-694
- 2I-PH-5F-PIMO
Meyers-Riggs, B. JWH-018 replacements. countyourculture, countyourculture: rational exploration of the underground, 6 Dec 2010. #AM-694
EMCDDA. New drugs in Europe, 2010, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2011. 700 kB.
Gwak, S; Arroyo-Mora, LE; Almirall, JR. Qualitative analysis of seized synthetic cannabinoids and synthetic cathinones by gas chromatography triple quadrupole tandem mass spectrometry. Drug Test. Anal., 1 Feb 2015, 7 (2), 121-130. 1.1 MB. https://doi.org/10.1002/dta.1667 #18
Kneisel, S; Auwärter, V; Kempf, J. Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Test. Anal., 1 Aug 2013, 5 (8), 657-669. 285 kB. https://doi.org/10.1002/dta.1429
Montenarh, D; Hopf, M; Warth, S; Maurer, HH; Schmidt, P; Ewald, AH. A simple extraction and LC-MS/MS approach for the screening and identification of over 100 analytes in eight different matrices: Detection of 130 analytes in eight biosamples using only one LC-MS/MS method. Drug Test. Anal., 1 Mar 2015, 7 (3), 214-240. 593 kB. https://doi.org/10.1002/dta.1657
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
Grigoryev, A; Kavanagh, P; Melnik, A. The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography – mass spectrometry. Drug Test. Anal., 1 Feb 2013, 5 (2), 110-115. 313 kB. https://doi.org/10.1002/dta.1336
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #49
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #3. AM-694
Davidson, C; Opacka-Juffry, J; Arevalo-Martin, A; Garcia-Ovejero, D; Molina-Holgado, E; Molina-Holgado, F. Spicing up pharmacology: A review of synthetic cannabinoids from structure to adverse events. In Adv. Pharmacol.; , Elsevier, 1 Jan 2017; pp 135–168. 458 kB. https://doi.org/10.1016/bs.apha.2017.05.001 #AM-694
Makriyannis, A; Deng, H. Cannabimimetic indole derivatives . Patent US 6900236, 31 May 2005. #AM694
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #33
Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #AM-694
Hasegawa, T; Takahashi, K; Saijo, M; Fukiwake, T; Motoki, Y. Current situation and issues for analyzing illegal drug products. Yakugaku Zasshi, 1 Jan 2013, 133 (1), 7–11. 396 kB. https://doi.org/10.1248/yakushi.12-00247-2 #3 GC,MS